Freenome's novel multiomics blood test for colorectal cancer detected advanced adenomas with a 41 percent sensitivity at 90 percent specificity, according to results from its Ai-Emerge study.
Researchers examined results from 522 patients during the study. Compared to the FDA-approved mSEPT9 blood test, Freenome's test had a higher sensitivity (41 percent to 22 percent).
Compared to stool-based tests, Freenome's sensitivity for advanced adenomas outperformed fecal immunochemical testing (24 percent) and was comparable to FIT-DNA testing (42 percent).
The new results supplement previously reported data that showed Freenome's test detected stage 1 and stage 2 CRC at a sensitivity of 94 percent and a specificity of 94 percent.